Voronoi, Inc. (KOSDAQ:310210)

South Korea · Delayed Price · Currency is KRW

201,000

+30,200 (17.68%)

Jun 29, 2026, 3:30 PM KST

73.88% (1Y)

Market Cap	3.62T +90.3%
Revenue (ttm)	7.51B
Net Income	-50.60B
EPS	-2,800.26
Shares Out	18.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,577
Open	179,100
Previous Close	170,800
Day's Range	175,800 - 203,500
52-Week Range	103,600 - 375,500
Beta	1.27
Analysts	Buy
Price Target	375,000.00 (+86.57%)
Earnings Date	Aug 14, 2026

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 140

Stock Exchange KOSDAQ

Ticker Symbol 310210

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 310210 stock is "Buy." The 12-month stock price target is ₩375,000, which is an increase of 86.57% from the latest price.

Price Target

₩375,000

(86.57% upside)

Analyst Consensus: Buy

Stock Forecasts